Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database

被引：8

作者：

George, Prethibha ^{[1
]}

Jagun, Oladayo ^{[1
,4
]}

Liu, Qing ^{[1
]}

Wentworth, Charles ^{[1
]}

Napatalung, Lynne ^{[1
,2
]}

Wolk, Robert ^{[3
]}

Anway, Susan ^{[3
]}

Zwillich, Samuel H. ^{[3
]}

机构：

[1] Pfizer Inc, New York, NY USA

[2] Mt Sinai Hosp, New York, NY USA

[3] Pfizer Inc, Groton, CT USA

[4] Pfizer Inc, 66 Hudson Blvd East, New York, NY 10001 USA

来源：

JOURNAL OF DERMATOLOGY | 2023年 / 50卷 / 09期

关键词：

alopecia areata; autoimmune and inflammatory disease; comorbidities; mental health; US claims; QUALITY-OF-LIFE; COMORBIDITY PROFILES; ADULTS; ONSET;

D O I：

10.1111/1346-8138.16839

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Alopecia areata (AA) is associated with an increased burden of autoimmune and inflammatory disease and mental health conditions that may have a negative impact on quality of life. However, the exact burden of comorbidities on US patients with AA and the clinical subtypes alopecia totalis (AT) and alopecia universalis (AU) compared with those without AA is not well understood. This retrospective cohort study aimed to assess the incidence rates and prevalence of AA and its clinical subtypes and examine the autoimmune and inflammatory disease and mental health condition diagnosis burden in US patients with AA and a matched cohort without AA. The Optum Clinformatics Data Mart database was used to select patients aged =12 years enrolled between October 1, 2016, and September 30, 2020, who had two or more AA diagnosis codes for the AA cohort. Three patients without AA were age-, sex-, and race-matched to each patient with AA. Autoimmune and inflammatory diseases and mental health conditions were evaluated at baseline and up to 2 years after the index date. In total, 8784 patients with AA (599 with AT/AU) and 26 352 matched patients without AA were included. The incidence rate of AA was 17.5 per 100 000 person-years (PY; AT/AU: 1.1 per 100 000 PY; non-AT/AU: 16.3 per 100 000 PY), and the prevalence was 54.9 per 100 000 persons (AT/AU: 3.8; non-AT/AU: 51.2). Patients with AA had a higher prevalence of autoimmune and inflammatory diseases than the matched non-AA cohort, including allergic rhinitis (24.0% vs 14.5%), asthma (12.8% vs 8.8%), atopic dermatitis (8.3% vs 1.8%), and psoriasis (5.0% vs. 1.6%). The proportions of anxiety (30.7% vs 21.6%) and major depressive disorder (17.5% vs 14.0%) were higher in patients with AA than those without AA. Patients with AT/AU generally had a greater prevalence of autoimmune and inflammatory disease and mental health conditions than patients with non-AT/AU AA.

引用

页码：1121 / 1128

页数：8

共 37 条

[1]

Abedini Robabeh, 2018, Int J Womens Dermatol, V4, P91, DOI [10.1016/j.ijwd.2017.07.001, 10.1016/j.ijwd.2017.07.001]

[2] Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity [J].